Guess which ASX healthcare stock is rocketing almost 50% on Friday

This stock is avoiding the market weakness on Friday. But why?

| More on:
A woman jumps for joy with a rocket drawn on the wall behind her.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market may be falling today, but that hasn't stopped Biotron Ltd (ASX: BIT) shares from rocketing.

In morning trade, the ASX healthcare stock is up almost 50% to 11 cents.

Why is this ASX healthcare stock rocketing?

Investors have been scrambling to buy the antiviral therapies developer's shares this morning after it released an update on its Phase 2 study of BIT225.

BIT225 is Biotron's lead compound. It is in Phase 2 development for the treatment of HIV-1 and Hepatitis C virus infections.

According to the release, preliminary analyses of data from the BIT225-010 Phase 2 clinical trial provide confirmation, and extension, of the results of previous trials in people infected with HIV-1.

The ASX healthcare stock explained that the double-blind placebo-controlled Phase 2 trial was designed to characterise the effect of BIT225 (200 mg, once daily for 24 weeks) added to a standard of care antiretroviral therapy (cART) in 27 treatment naive people infected with HIV-1. This comprises 18 using BIT225 and 9 using a placebo.

Study participants were followed for a one-month period following 24-weeks of BIT225 or placebo dosing, with all individuals continued on cART as per standard treatment guidelines post-study.

Preliminary analysis of the safety data has shown that BIT225 was safe and generally well tolerated at the 200mg once daily dose, with no deaths or drug-related serious adverse events.

As for efficacy, preliminary analyses of the HIV-1 plasma viral load (pVL) data suggest that the addition of BIT225 to cART results in a more rapid reduction in plasma virus levels during the second phase of viral decay, compared to cART alone.

Furthermore, preliminary analyses of blood immune cell populations showed changes in specific immune cell populations in the BIT225 group compared to cART alone.

Management commentary

The ASX 200 healthcare stock's managing director, Dr Michelle Miller, was pleased with the trial results. She said:

The positive outcomes from this trial further our understanding of BIT225. The blood (plasma) viral load data in particular should be highlighted, as it suggests that BIT225 is having an impact on a critical phase of viral decay when latent reservoirs are established. Current cART is efficient at rapidly and durably reducing virus levels in the blood, but this does not translate into clearance of latent reservoirs.

The observed changes to immune markers and cells further the results from the previous 009 trial and suggest the utility of targeting viroporins as a new class of antiviral drugs. The results reported here are preliminary, and ongoing analysis of the BIT225-010 study, as well as its companion study, BIT225-011 in HIV-1 chronically infected individuals, will be reported when complete.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Healthcare Shares

Guess which ASX 200 share is up 7% after smashing FY24 guidance

This growing company has outperformed expectations in FY 2024 with another impressive 12 months.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Sigma shares race to another record high. What's next?

What's next for the new-and-improved healthcare giant?

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

Up 120% in a year, ASX 200 healthcare stock dips on US acquisition

The ASX 200 healthcare company announced a strategic new US acquisition.

Read more »

Medical or healthcare workers grasp hands in the universal expression of teamwork
Healthcare Shares

Here's how the ASX 200 market sectors stacked up last week

Healthcare was the strongest sector last week, with market darling Pro Medicus surging yet again.

Read more »

Three happy girls on jumping motion with inflatable mattresses at the beach.
Share Gainers

3 ASX All Ords shares leading the charge in 2025

These ASX All Ords shares have soared 16% to 37% already in 2025.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

3 ASX 200 healthcare stocks with 'strong return potential' in 2025

A leading investment manager expects 2025 will be a good year for these ASX 200 healthcare companies.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Why are Mesoblast shares in a trading halt?

The biotech company requested a trading halt before the market open on Friday. Here's why.

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

ASX All Ords stock rockets 18% on FDA clearance

This stock is making very healthy returns on US news.

Read more »